Novartis Venture Fund is a corporate venture capital firm in Switzerland that focuses on companies that develop novel therapeutics and platforms. Founded 1996 in Basel-Stadt, Switzerland by Argeris Karabelas, it invests in early stage ventures, late stage venture, post-IPO, secondary markets, seed, series A, series B, series C, and post-IPO equity. Its portfolio companies include TScan Therapeutics, GenSight Biologics, FORMA Therapeutics, Arctos Medical, and Enterprise Therapeutics. As of March 2020, Novartis Venture Fund has made 200 investments. Their most recent investment was on January 10, 2020, when TScan Therapeutics raised $35M. Novartis Venture Fund has had 51 exits, the most notable of which include PTC Therapeutics, Bicycle Therapeutics, and Akebia Therapeutics. The company has raised three funds, their latest being Novartis Option Fund (NOF). This fund was announced on January 1, 2009 and raised a total of $200M.
Head of Legal
Chief Financial Officer
Chairman, Option Fund
Documentaries, videos and podcasts